Table 3

Clinical and laboratory data regarding obesity/T2DM

Eradication therapy
S1 (n=20)S3 (n=20)P value
Body weight (kg)52.9
(51.6–70.2)*
53.9
(49.7–70.8)
0.35
Percent body fat (%)26.7±8.3†26.4±8.10.43
Body mass index23.0±3.422.9±3.60.26
Serum triglycerides (mg/dL)80.5
(69.8–139.3)
109.0
(65.8–155.3)
0.35
Fasting blood glucose (mg/dL)105
(91–102)
108
(87–103)
0.99
Insulin (μIU/mL)4.48
(2.62–6.81)
3.17
(1.86–9.56)
0.93
HOMA-R1.02
(0.62–1.99)
2.05
(0.42–3.14)
0.78
HbA1c (NGSP %)5.6
(5.3–6.0)
5.6
(5.4–5.9)
0.10
Adiponectin (μg/mL)9.2
(7.1–12.8)
10.4
(6.5–14.1)
0.41
CRP (ng/mL)511
(187–1083)
408
(202–1180)
0.18
Desacyl – ghrelin (fmol/L)89.8±40.877.6±36.70.14
Active ghrelin (fmol/L)8
(6–10.5)
5
(0–6.25)
0.003
Leptin (ng/mL)8.1
(5.8–13.0)
8.5
(5.9–15.2)
0.03
  • *Median (IQR).

  • †Mean±SD.

  • CRP, C reactive protein; HbA1c, glycated haemoglobin; T2DM, type 2 diabetes mellitus. HOMA-R, homeostasis model assessment-insulin resistance.